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Objective: To compare healthcare resource utilization and healthcare costs between COPD
patients who used multiple long-acting inhalers versus those who used a single long-acting
inhaler.
Methods: COPD patients meeting study inclusion criteria were identified in the Market Scan
database (2004e2008) and were classified as being a multiple- or single-inhaler user. 11,747
multiple- and single-inhaler users were matched on baseline characteristics to balance disease
severity. Patients were followed for 12 months. Incremental differences between the two
groups were estimated for: number of exacerbations; time to first exacerbation; all-cause
and COPD-related inpatient admissions, inpatient days, emergency room visits, urgent care
visits, outpatient visits, and other medical services visits; all-cause and COPD-related health-
care costs. Multivariate regression analyses were also used to control for a number of poten-
tially confounding factors.
Results: After controlling for a number of potentially confounding factors, multiple-inhaler
users experienced significantly more exacerbations (0.52; p < .0001) and had a higher risk
of exacerbation (HR Z 1.40; p < .0001) than single-inhaler users. Multiple-inhaler users also
incurred significantly more inpatient admissions (IRR Z 1.15; p < .0001), inpatient days
(IRR Z 1.20; p < .0001), urgent care visits (IRR Z 1.10; p Z 0.0026), outpatient visits
(IRR Z 1.06; p < .0001), and other medical services visits (IRR Z 1.12; p Z <.001) than
single-inhaler users, resulting in significantly higher all-cause health care costs ($3,319;up Inc., 1000 rue de la Gauchetie`re Ouest, Bureau 1200, Montre´al, QC H3B 4W5, Canada. Tel.: þ1 514
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1862 A.P. Yu et al.p < .0001). Results of COPD-related resource use and costs were comparable.
Conclusions: After controlling for a number of potentially confounding factors, multiple-
inhaler users had more exacerbations, a higher risk of exacerbation, and higher healthcare
resource utilization and costs compared to single-inhaler users.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
respiratory disease afflicting primarily middle-aged and
older adults and is responsible for significant morbidity and
mortality throughout the world.1 In 2009, the American
Lung Association (ALA) estimated that 12.1 million Ameri-
cans were diagnosed with COPD, but that the actual prev-
alence of COPD in the United States was almost twice as
high, indicating a substantial amount of underdiagnosis.2
Because of the aging population, the progressive nature
of the disease, and the lack of therapies to reverse the
pathological deterioration of the lung, COPD is a leading
cause of death in the United States and continues to
increase in prevalence.3,4 COPD creates a heavy economic
burden on the healthcare system and society, with costs
estimated at nearly $50 billion per year ($US 2010) in
the US.5
Treatment guidelines for COPD, including those set forth
by the Global Initiative for Chronic Lung Disease (GOLD),
recommend varying treatment according to a patient’s
disease severity,1,6 including short-acting inhalers that are
considered first-line treatment for patients with mild
COPD, long-acting bronchodilators, [long-acting beta2
agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs)] that are for daily maintenance therapy in patients
with moderate to very severe disease, inhaled corticoste-
roids (ICSs) that are recommended in severe and very
severe patients with repeated exacerbations, and
phosphodiasterase-4 inhibitors that are recommended as
add-on therapy to long-acting bronchodilators in severe and
very severe patients.1,6
Reducing exacerbations is an important goal of COPD
management,1 as exacerbations have been linked to
a myriad of poor outcomes including sustained decreased
lung function, increased depression, and diminished health
status.1 COPD exacerbations also create a substantial
economic burden.7 The cost of a severe exacerbation in the
United States  one that results in hospitalization or death
 is approximately $11,261, while the cost of a non-severe
exacerbation in the United States is $1509 ($US 2008).8 This
makes exacerbations one of the major contributors to the
large economic burden of COPD, accounting for 35%e45% of
the total cost of COPD treatment.9e11
Though many patients with COPD are prescribed main-
tenance medications, patients may not experience the full
therapeutic benefit of these products if adherence and
persistence are low. Poor adherence to COPD therapy has
been linked to a greater likelihood of exacerbations and
increased risk of mortality.11 Further complicating matters
is the fact that many patients with COPD are often
prescribed multiple inhaled medications, each with
a distinct, complex device and a unique set of instructionsfor proper use.12 Therefore, treatment complexity itself
may contribute to the poor rates of adherence and persis-
tence seen among patients with COPD. A recent study
demonstrated an association between treatment
complexity and poor persistence, which was analyzed via
time to treatment discontinuation, and poor treatment
adherence, which was measured by proportion of days
covered. In that study, patients with COPD who used two or
more long-acting inhalers concomitantly were 34% less
likely to be adherent to therapy and had a 40% higher
treatment discontinuation rate compared to patients using
a single long-acting inhaler, even after controlling for
proxies of COPD severity.13 Other studies have shown
similar results14e16; however, there is limited information
on the association between COPD treatment complexity
and key outcomes such as exacerbations, healthcare
resource utilization, and healthcare costs.
The objective of the present study was to compare the
rates of exacerbations, healthcare resource utilization, and
healthcare costs associated with inhaler medication
complexity in patients with COPD using multiple long-acting
bronchodilator inhalers concurrently and patients using
a single bronchodilator inhaler.
Methods
Data source
Healthcare claims data were extracted from a combined
database of the Thomson MarketScan Commercial Database
(TMCD) and MarketScan Medicare Supplemental and Coor-
dination of Benefits (COB) database between January 2004
and December 2008. The TMCD includes fully integrated
patient-level data, including inpatient, outpatient, phar-
macy, and laboratory services and enrollment data from
approximately 25 million lives covered annually by self-
insured employers and private health insurance plans. The
MarketScan Medicare COB database focuses on patients
who receive supplemental Medicare benefits through
employer-sponsored health plans; it contains data on the
employer-paid portion, Medicare-paid benefits (i.e., COB
amount), and patients’ out-of-pocket expenses of their
medical and pharmacy services. These databases are fully
de-identified and HIPAA compliant.
Cohort selection
Multiple-inhaler users and single-inhaler users were iden-
tified based on their prescription drug claims among all the
patients who received at least two diagnoses for COPD (ICD-
9-CM: 490.xxe492.xx or 494.xxe496.xx). Multiple-inhaler
users were patients with COPD who had at least two
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inhalers concomitantly or at least one long-acting bron-
chodilator inhaler and an ICS inhaler concomitantly for at
least 7 consecutive days. Patients who had no record of
using more than one long-acting bronchodilator inhaler
concomitantly or a long-acting bronchodilator and a sepa-
rate ICS inhaler concomitantly at any time within a period
of at least one year were defined as single-inhaler users.
Long-acting bronchodilator inhalers were defined as being
LAMAs, LABAs, and LABA/ICS combination inhalers. As
LABA/ICS combination inhalers are contained in one device,
these were considered to be a single-inhaler.
Because patients newly initiated on a single long-acting
inhaler were more likely to be newly diagnosed with COPD
and could have less severe disease than patients initiated
on multiple maintenance inhalers, the index date for each
patient was randomly selected to minimize the intrinsic
imbalance in disease severity. For a single-inhaler user, any
date of a long-acting inhaler prescription that was
preceded by at least 6 months of health plan continuous
eligibility and followed by at least 12 months of continuous
eligibility was a potential index date. For a multiple-inhaler
user, any prescription date during a combination regimen
that was preceded by at least 6 months of health plan
continuous eligibility and followed by at least 12 months of
continuous eligibility was a potential index date. In addi-
tion to these criteria, to be considered as a potential index
date, the patient had to be at least 40 years of age on that
date and have received at least two prescriptions for
a long-acting inhaler within 12 months following the index
date.
Once the index date was selected, the baseline period
was defined as the 6 months prior to the index date, and
the study period was defined as the 12 months after the
index date. The inhaler(s) being prescribed or used on the
index date was defined as the index inhaler(s).
Patients who use multiple long-acting bronchodilator
inhalers, with or without ICS, are likely to have more severe
COPD compared to single-inhaler users, with the exception
of patients using fixed-dose combination in a single-inhaler
device. However, due to the absence of severity-specific
clinical data in our dataset, an exact matching was per-
formed to balance baseline patient characteristics among
two cohorts: single-inhaler users and multiple-inhaler
users. Single- and multiple-inhaler users were matched in
a 1:1 ratio based on patient characteristics and several
baseline characteristics that were used as proxies for
disease severity, including age, gender, index year, COPD
subtype based on ICD-9 code classification (bronchitis,
chronic bronchitis, emphysema, bronchiectasis, extrinsic
allergic alveolitis, or chronic airway obstruction), baseline
Charlson Comorbidity Index (CCI) score (Charlson, 1987),
baseline COPD pharmacotherapeutic class used (LAMAs,
LABAs, oral or inhaled corticosteroids, methylxanthines, or
antibiotics), number of COPD prescriptions during the
baseline period, and number of COPD exacerbations during
the baseline period. Patients were matched based on the
exact characteristics. No grouping criteria were applied. By
matching and controlling for a comprehensive list of char-
acteristics measured during the baseline period, the
potential bias associated with the cohort selection based on
different treatment regimens was reduced.Outcomes and statistics
Patient characteristics
After matching, patients’ characteristics during the base-
line period, including demographics (age and gender),
index year, COPD prescriptions, CCI score, comorbidities,
number of COPD exacerbations, healthcare resource utili-
zation, and healthcare costs were summarized and
compared between single-inhaler and multiple-inhaler
users with the McNemar test for categorical variables and
the Wilcoxon signed rank test for continuous variables.
COPD exacerbations
Due to the absence of a clinical measure of COPD exacer-
bation severity in healthcare claims, COPD exacerbations
were defined as one of the following occurrences observed in
the claims database: 1) diagnosis-based exacerbation:
amedical claimwith a diagnostic code of COPD exacerbation
(ICD-9-CM code: 491.21 or 491.1x), 2) urgent care-based
exacerbation: a medical claim for a service during an inpa-
tient or emergency room visit with a diagnosis of COPD
exacerbation, or 3) prescription-based exacerbation:
a prescription for an antibiotic or a corticosteroid within 7
days following an outpatient visitwith a diagnosis of COPD, or
4) any exacerbation: an event which met the criteria for at
least one of the three aforementioned exacerbation types.
For additional granularity, diagnosis-based exacerbations
were further categorized into outpatient, inpatient, and
emergency room exacerbations while urgent care-based
exacerbations were categorized into inpatient and emer-
gency room exacerbations. Although these different defini-
tions of exacerbations are not a perfect reflection of
severity, they are a goodproxy for a range of severity of COPD
exacerbation events in the absence of severity-specific data.
The rates of exacerbation during the study period were
analyzed separately for each of the above definitions using
descriptive statistics. Univariate and multivariate linear
regression models with random effects for matched pairs
were used to estimate the incremental effect of using
multiple inhalers, relative to using a single-inhaler, on the
number of exacerbations within the one-year study period,
while Cox-proportional hazards models with random effects
for matched pairs were used to compare exacerbation rates
and the risk of experiencing an exacerbation during the study
period between single- and multiple-inhaler users. Multi-
variate regression models controlled for age, gender, exac-
erbation events at baseline, and common comorbidities with
a 5% or higher prevalence in at least one cohort, including
anemia, depression or anxiety, lower respiratory tract
infection, glaucoma, congestive heart failure, sleep disor-
ders, cataracts and visual disturbances, diabetes, ischemic
heart disease, upper respiratory tract infection, asthma,
arthritis, metabolic syndrome, and musculoskeletal disor-
ders. In addition, KaplaneMeier survival analyses were con-
ducted to depict the differences of the time to experience an
exacerbation event between both cohorts and log-rank tests
were used to compare differences between cohorts.
Healthcare resource utilization
The following types of healthcare resource utilization were
studied: 1) inpatient admissions, 2) inpatient days, 3) ER
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same day were included in the inpatient stay only), 4)
urgent care visits (sum of the number of days during inpa-
tient stays and emergency room visits), 5) outpatient visits
and 6) other medical services (including single delivery port
oxygen concentrators, portable gaseous oxygen systems
and nebulizers). COPD-related services were identified
from claims with a primary diagnosis for COPD.
As poorly managed COPD is likely to have an impact on
the severity of other comorbidities,1 both all-cause and
COPD-related utilization rates of these healthcare services
during the one-year study period were summarized for both
cohorts and compared using incidence rate ratios (IRR).
Generalized linear models (GLM) with a log link and
a negative binomial distribution were used in the between-
cohort comparisons.
Healthcare costs
Medical, pharmacy, and all-cause healthcare costs incurred
during the one-year study period were calculated and
compared between the single- and multiple-inhaler
cohorts. Medical costs included inpatient, emergency
room, urgent care (combined inpatient and emergency
room), outpatient, and other medical service costs. These
were further divided into all-cause and COPD-related costs.
All-cause medical costs represent all healthcare resource
use and costs regardless of the primary diagnosis. COPD-
related medical costs only include the costs of services
associated with claims carrying a primary diagnosis for
COPD. Similarly, all-cause pharmacy costs include costs for
all prescriptions, regardless of indication, whereas COPD-
related pharmacy costs only include costs associated with
prescriptions for the following medications: LAMAs, LABAs,
oral and inhaled corticosteroids, methylxanthines, and
antibiotics. All costs were calculated from the third-party
payer’s perspective using inflation-adjusted 2008 U.S.
dollars.
Incremental cost differences between the two cohorts
were estimated using GLM models with log link and gamma
distribution or two-part models for cost endpoints with
more than 5% of data with zero values, in which the first
part was a logistic model and the second a GLM model with
a log link and gamma distribution.
Healthcare resource utilization and healthcare cost
multivariate regression models controlled for age, gender,
baseline healthcare resource utilization, and common
comorbidities with a 5% or higher prevalence in at least one
cohort.
Statistical significance was set at a two-sided alpha-level
of 0.05 or less. All statistical analyses were performed using
SAS 9.2 (SAS Institute, Inc., Cary, NC).
Results
Patient characteristics
11,747 matched pairs of single- and multiple-inhaler users
with COPD (i.e. 23,494 patients) who met the inclusion
criteria were matched by age, gender, index year, COPD
subtype, baseline CCI score, pharmacotherapeutic classes
of COPD treatment used, number of COPD prescriptionsfilled and number of COPD exacerbations during the
baseline period. Figure 1 depicts the sample selection
methodology.
As shown in Table 1, the 11,747 matched pairs of single-
and multiple-inhaler users had a mean (SD) age of 66.0
(9.8) years, and over half (53.1%) were women. Similar
percentages of patients received antibiotics (42.9%), LABAs
(42.1%), LAMAs (41.9%), and oral or inhaled corticosteroids
(41.7%) during the 6-month baseline period while very few
received methylxanthines (0.8%). Patients experienced
a mean (SD) number of 0.2 (0.6) COPD exacerbations
during the baseline period.
Baseline prevalence of comorbidities was generally
comparable between the single-inhaler and multiple-
inhaler cohorts (Table 2). Although both cohorts were
matched on CCI score, statistically higher rates of upper
respiratory tract infection (14.6% vs. 12.9%), musculoskel-
etal disorders (38.7% vs. 35.5%), metabolic syndrome (23.3%
vs. 20.7%), and arthritis (19.0% vs. 16.4%, all comparisons:
p < .0001) were observed in the single-inhaler users, which
represents a generally higher residual comorbidity burden
for single-inhaler users after matching. Multiple-inhaler
users had statistically significant higher rates of asthma
(18.9% vs. 16.8%) compared to the single-inhaler users
(p < .0001). These differences were controlled for in
multivariate regression analyses.
Table 3 summarizes patients’ baseline healthcare
resource utilization, including inpatient visits, emergency
room visits, outpatient visits, other medical service visits,
and healthcare costs. At baseline, a significantly higher
percentage of patients in the single-inhaler cohort had at
least one emergency room visit (10.4% vs. 9.0%) and higher
mean number of outpatient visits (19.6 vs. 18.9) and
emergency room visits (0.5 vs. 0.4, all comparisons:
p < .0001) compared to the multiple-inhaler cohort. On the
other hand, single-inhaler users incurred substantially
lower drug costs, both for total drug costs ($2318.4 vs.
$2747.3) and COPD-related drug costs ($293.9 vs. $455.5),
and lower medical costs ($4090.7 vs. $4154.5) compared to
multiple-inhaler users during the 6-month baseline period
(all comparisons: p < .0001).COPD exacerbations
During the 12-month study period, 46.4% of the multiple-
inhaler users experienced at least one exacerbation event
compared to 36.5% of the single-inhaler users (Table 4). As
shown in Table 5, multiple-inhaler users had on average
1.55 (3.59) exacerbations, compared to the 1.03 (2.63)
exacerbation events observed among the single-inhaler
users (p < .0001) (Table 5). After adjusting for potential
confounding factors, multiple-inhaler users experienced
0.524 more exacerbations (for any type of exacerbation)
compared to single-inhaler users during the study period
(p < .0001). Similarly adjusted incremental exacerbation
numbers were 0.220 for diagnosis-based, 0.237 for urgent
care-based and 0.244 for prescription-based definitions (all
comparisons, p < .0001).
In addition, after controlling for a number of potential
confounding factors, multiple-inhaler users also had
a significantly higher time-adjusted risk of experiencing
Patients with  2 COPD Diagnosis Codes 
N=1,038,654
Patients with  2 Prescriptions for a Long Acting Inhaler Within one Year 
N = 289,176 
Patients Aged  40 and Continuous 
Eligibility‡
N = 45,554 
Matched Patients
          N=23,494 
Patients Aged  40 and Continuous 
Eligibility‡
N=140,529
Multiple Inhaler 
Users * 
N = 68,223 
Single Inhaler  
Users † 
N = 220,943 
Figure 1 Sample selection flowchart. )Patients with COPD who had at least two occasions of filling two or more long-acting
bronchodilator inhalers concomitantly or at least one long-acting bronchodilator inhaler and a separate ICS inhaler concomi-
tantly for at least 7 consecutive days. yPatients who had no record of filling more than one long-acting bronchodilator inhaler
concomitantly or a long-acting bronchodilator and a separate ICS inhaler concomitantly at any time within a period of at least 18
months. zBefore applying the age exclusion criterion, there were 45,798 multiple-inhaler users and 147,300 single-inhaler users
with continuous eligibility. The minimum age requirement excluded 244 and 6771 patients, respectively. ΔThere were 11,747
single- and 11,747 multiple-inhaler matched patients (23,494 patients).
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regardless of whether exacerbation was defined by medical
service claims with COPD diagnosis (adjusted hazard ratio
[HR] Z 1.57, 95% confidence interval [CI]: 1.46e1.68),
urgent care visits with the diagnosis (adjusted HR Z 1.39,
95% CI: 1.30e1.49), or by prescription drugs for antibiotics
or corticosteroids after a medical visit with the diagnosis
(adjusted HR Z 1.41, 95% CI: 1.34e1.48, all comparisons
p < .0001). Multiple-inhaler users had a 40% higher risk of
exacerbation event compared to single-inhaler users
(adjusted HRZ 1.40, 95% CI at 1.34 to 1.46, p < .0001) for
any type of exacerbation event.
Figure 2 depicts results from the Kaplan Meier analyses
with single-inhaler users consistently showing a longer time
to the first exacerbation compared to multiple-inhaler
users across all three definitions of exacerbation.
Healthcare resource utilization
After adjusting for potential confounders, Table 6 shows
multiple-inhaler users with significantly higher healthcare
resource utilization incidences compared to single-inhaler
users for inpatient admissions (adjusted IRR Z 1.15, 95%
CI: 1.09e1.21,p < .0001), inpatient days (adjusted
IRR Z 1.20, 95% CI: 1.11e1.30, p < .0001), urgent care
visits (adjusted IRR Z 1.10, 95% CI: 1.04e1.18,p Z 0.0026), outpatient visits (adjusted IRR Z 1.06, 95%
IRR: 1.03e1.09, p < .0001), and other medical visits
(adjusted IRR Z 1.12, 95% CI: 1.07e1.18, p < .0001).
Similarly, multiple-inhaler users had higher incidences of
COPD-related healthcare resource utilization compared to
single-inhaler users for inpatient admissions (adjusted
IRR Z 1.64, 95% CI: 1.43e1.89), inpatient days (adjusted
IRRZ 1.82, 95% CI: 1.54e2.16), urgent care visits (adjusted
IRRZ 1.76, 95% CI: 1.50e2.07), outpatient visits (adjusted
IRR Z 1.59, 95% CI: 1.51e1.68), and other medical service
visits (adjusted IRR Z 1.24, 95% CI: 1.16e1.32, all
comparisons: p < .0001). However, the number of emer-
gency room visits was not statistically significantly different
between single- and multiple-inhaler users.
Healthcare costs
Table 7 summarizes the differences in healthcare costs
incurred by patients in the single-inhaler and multiple-
inhaler cohorts during the one-year study period. Single-
inhaler users incurred a mean (SD) cost of $17,007
(28,806) per patient in total healthcare cost, significantly
lower than the mean (SD) cost of $19,650 (27,838) per
patient among multiple-inhaler users. Single-inhaler users
also incurred lower total pharmacy costs ($5372  $4657 vs.
$7013  $5163) and lower all-cause medical costs
Table 1 Baseline characteristics of matched pairs of
single- and multiple-inhaler users.
Matching criteria Single- and
multiple-inhaler
users
Number of Matched Pairs, Na 11,747
Demographics
Age (mean  SD) 66.0  9.8
Female, N (%) 6232 (53.1)
Index Year, N (%)
2004 1301 (11.1)
2005 2211 (18.8)
2006 3014 (25.7)
2007 5221 (44.4)
COPD treatments
Drug treatment by class, N (%)
LAMAs 4921 (41.9)
LABAs 4951 (42.1)
Corticosteroids (Oral and Inhaled) 4904 (41.7)
Methylxanthines 91 (0.8)
Antibiotics 5034 (42.9)
COPD prescriptions, N (%)
0e5 7425 (63.2)
5e10 1941 (16.5)
>10 709 (6.0)
COPD exacerbations (any type)
during baseline period (mean  SD)
0.2  0.6
Charlson comorbidity index score
(mean  SD)
1.0  0.9
a Single-and multiple-inhaler users were exactly matched in
a 1:1 ratio based on baseline characteristics and proxies for
disease severity, including age, gender, index year, COPD
subtype based on ICD-9 code classification, and baseline CCI
score, COPD pharmacotherapeutic class used, number of COPD
prescriptions and number of COPD exacerbations. No grouping
criteria were applied.
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ences were statistically significant before and after
controlling for a number of potential confounding factors
(p < .0001). After controlling for potential confounders,
multiple-inhaler users incurred an additional $3319 in all-
cause healthcare costs (p < .0001), composed of an addi-
tional $1776 in all-cause pharmacy costs (p < .0001) and an
additional $1586 in all-cause medical costs (p < .0001)
compared with single-inhaler users. Overall, multiple-
inhaler users reported significant incremental costs for
inpatient care ($519; p Z 0.0080), outpatient visits ($410;
p Z 0.0080), and other medical service visits ($251;
p < .0001).
Similarly, adjusted differences in COPD-related costs
between single-inhaler and multiple-inhaler users showed
similar trends as overall healthcare costs. Single-inhaler
users incurred $976 less COPD-related pharmacy costs, $199
less inpatient costs, $142 less outpatient costs, and $138
less other medical service costs relative to multiple-inhaler
users (all comparisons p < .0001). However, emergency
room costs were not statistically significantly different
between single- and multiple-inhaler users.Discussion
In this study, patients with COPD using multiple long-acting
inhalers experienced more exacerbations within a 12-
month study period compared to patients using a single
long-acting inhaler. Additionally, multiple-inhaler users had
more inpatient, outpatient, and other medical service visits
and incurred higher costs for both all-cause and COPD-
related healthcare. These differences remained statisti-
cally significant after controlling for a number of potential
confounding factors, suggesting that the differences in
clinical and economic outcomes between single- and
multiple-inhaler users exist beyond differences in age,
gender, comorbidities, number of COPD exacerbation
events, prior COPD medication use, and the type of COPD
diagnosis. However, although a number of precautions were
undertaken to minimize the potential selection bias by
treatment severity, no direct information was available on
COPD severity, as measured by the spirometry test (e.g.,
FEV1), meaning that some confounding effect may remain.
To reduce the potential selection bias, the authors took
a number of steps to minimize the confounding effect of
disease severity and other factors on treatment outcomes.
First, patients were exactly matched on age, sex, index
year, type of COPD drug therapy, number of COPD
prescriptions, and the number of exacerbation events
during the baseline period. Second, the index date for each
patient was randomly selected from all potential index
dates to avoid selecting newly diagnosed patients in rela-
tively early stages of the disease. Third, multivariate
regression analyses further controlled for comorbidities
with a prevalence of at least 5% and healthcare utilization
in the baseline period. Thus, while it was not possible to
explicitly control for COPD severity due to the limitations of
the dataset, it can be reasonably inferred that the differ-
ences in outcomes observed in this study were unlikely to
be fully determined by disease severity.
Additionally, when comparing the baseline characteris-
tics between the two cohorts after exact matching, single-
inhaler users exhibited a greater number of medical
comorbidities (except asthma) and higher baseline medical
resource utilization compared to multiple-inhaler users.
Therefore, the finding that patients using multiple inhalers
experienced more exacerbation events during the study
period and had higher healthcare resource utilization than
single-inhaler users, in spite of multiple-inhaler users
having more favorable baseline characteristics, also
suggests an association between a reduced medication
burden and COPD-related outcomes.
In this study, due to the absence of severity-specific
clinical data in healthcare insurance claims, we defined
a COPD exacerbation in four distinct ways. The various
definitions reflected, to an extent, a range of exacerbation
severity, including severe events that required urgent care
visits (inpatient stay or emergency room visit) and
moderate exacerbations managed with prescription drugs
in the outpatient setting. The consistency of results across
all definitions suggests that, among other factors, treat-
ment complexity could contribute to increase patients’ risk
of exacerbation across a range of exacerbation types. It is
also likely that the risk of exacerbation, healthcare
Table 2 Prevalence of comorbidities during the 6-month baseline period.
Comorbidities, N (%) Single-inhaler
users N Z 11,747
Multiple-inhaler
users (All) N Z 11,747
P-Value
Anemia 565 (4.8) 515 (4.4) 0.1200
Angina 212 (1.8) 229 (1.9) 0.4129
Arthritis 2237 (19.0) 1929 (16.4) <.0001**
Asthma 1971 (16.8) 2215 (18.9) <.0001**
Cachexia 1 (0.0) 0 (0) e
Carcinoma in situ of respiratory system 3 (0.0) 10 (0.1) 0.0522
Cataracts and visual disturbances 1025 (8.7) 1043 (8.9) 0.6785
Chronic renal failure 103 (0.9) 103 (0.9) e
Congestive heart failure 730 (6.2) 738 (6.3) 0.8306
Coronary artery disease 1 (0.0) 2 (0.0) e
Depression or anxiety 612 (5.2) 550 (4.7) 0.0616
Diabetes 1238 (10.5) 1132 (9.6) 0.0219*
Glaucoma 700 (6.0) 716 (6.1) 0.6575
Hypoxemia with cognitive impairment 177 (1.5) 185 (1.6) 0.6741
Ischemic heart disease 1683 (14.3) 1768 (15.1) 0.1170
Lower respiratory tract infection 630 (5.4) 607 (5.2) 0.5033
Lung cancer 130 (1.1) 140 (1.2) 0.5428
Malnutrition and weight loss 105 (0.9) 88 (0.7) 0.2162
Metabolic syndrome 2733 (23.3) 2437 (20.7) <.0001**
Musculoskeletal disorders 4549 (38.7) 4168 (35.5) <.0001**
Nutritional deficiencies 92 (0.8) 72 (0.6) 0.1183
Peptic ulcer disease 36 (0.3) 33 (0.3) 0.7180
Reflux esophagitis 143 (1.2) 110 (0.9) 0.0365*
Sleep disorder 773 (6.6) 794 (6.8) 0.5817
Upper respiratory tract infection 1718 (14.6) 1516 (12.9) 0.0001**
*Significant at the 5% level.
**Significant at the 1% level.
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COPD exacerbations, particularly severe exacerbations
requiring hospitalization, have been shown to be the main
driver of COPD healthcare utilization and healthcare costs.Table 3 Health Care resource utilization and healthcare costs
Resource utilization and cost types Si
us
Baseline resource utilization
1 Inpatient visit, N (%) 11
1 Emergency room visit, N (%) 12
Length of stay (days; mean  SD) 1.
Number of inpatient admissions (mean  SD) 0.
Number of outpatients visits (mean  SD) 19
Number of emergency room visits (mean  SD) 0.
Number of other medical service visits (mean  SD) 3.
Baseline healthcare costs ($2008; mean  SD)
Inpatient services 12
Outpatient services 22
Emergency room services 64
Other medical services 51
COPD pharmacy costs 29
Total pharmacy costs 23
Total medical costs 40
Total health care costs (Medical þ Pharmacy) 64
*Significant at the 5% level.
**Significant at the 1% level.Similar findings were presented in a study by Chrischilles
and colleagues15 (2002) comparing patients using a single
ipratropium/albuterol inhaler with patients using the two
medications in separate inhalers. Chrischilles et al. showedduring the 6-month baseline period.
ngle-inhaler
ers N Z 11,747
Multiple-inhaler
users N Z 11,747
P-Value
05 (9.4) 1125 (9.6) 0.6544
27 (10.4) 1053 (9.0) 0.0001**
0  5.2 1.0  5.1 0.4124
1  0.3 0.1  0.3 0.8367
.6  21.7 18.9  21.3 0.0034**
5  2.5 0.4  2.0 <.0001**
9  8.1 3.8  7.4 0.8648
69.7  6820.5 1358.3  7760.4 0.3468
39.3  5066.4 2157.4  4286.0 0.4920
.3  370.5 51.7  338.3 0.0003**
7.4  2182.0 587.1  4459.4 0.0783
3.9  322.6 455.5  475.9 <.0001**
18.4  2313.3 2747.3  2510.4 <.0001**
90.7  9587.1 4154.5  10,695.0 0.8981
09.0  10,125.0 6901.8  11,183.1 <.0001**
Table 4 Comparison of exacerbation rates between the single- and multiple-inhaler cohorts.
Exacerbation rates N (%) Unadjusted hazard
ratioa (95% CI)
P-Value Adjusted hazard
ratiob (95% CI)
P-Value
Single-inhaler
cohort
Multiple-inhaler
cohort
Any exacerbation 4292 (36.5%) 5452 (46.4%) 1.39 (1.33e1.46) <.0001** 1.40 (1.34e1.46) <.0001**
Exacerbation diagnosis 1385 (11.8%) 2078 (17.7%) 1.57 (1.46e1.68) <.0001** 1.57 (1.46e1.68) <.0001**
Outpatient 1032 (8.8%) 1519 (12.9%) 1.51 (1.39e1.64) <.0001** 1.51 (1.39e1.64) <.0001**
Inpatient 477 (4.1%) 815 (6.9%) 1.75 (1.56e1.96) <.0001** 1.77 (1.57e1.99) <.0001**
Emergency room 126 (1.1%) 170 (1.4%) 1.35 (1.07e1.70) 0.0106* 1.33 (1.04e1.69) 0.0223*
Exacerbation urgent care 1506 (12.8%) 2026 (17.2%) 1.38 (1.29e1.48) <.0001** 1.39 (1.30e1.49) <.0001**
Inpatient 1249 (10.6%) 1710 (14.6%) 1.40 (1.30e1.51) <.0001** 1.42 (1.31e1.53) <.0001**
Emergency room 353 (3.0%) 463 (3.9%) 1.33 (1.16e1.53) <.0001** 1.34 (1.16e1.55) <.0001**
Exacerbation prescription 3335 (28.4%) 4327 (36.8%) 1.40 (1.33e1.47) <.0001** 1.41 (1.34e1.48) <.0001**
*Significant at the 5% level.
**Significant at the 1% level.
a HR > 1 indicates that multiple-inhaler users had a greater exacerbation rate compared to single-inhaler users.
b Multivariate regression models were adjusted for confounding factors including patient demographics, number of exacerbations at
baseline, Charlson Comorbidity Index score, prior COPD drug therapy, and COPD associated comorbidities.
1868 A.P. Yu et al.that patients initiated on the combination inhaler had
a significantly lower risk of emergency room visits or inpa-
tient visits, shorter inpatient stays, and lower monthly
healthcare charges than those using the medications in
separate inhalers. The present study broadens the analysis
by Chrischilles and the use of multiple versus single inhalers
across the range of COPD maintenance medications.
However, both Chrischilles’ and the present study were
based on healthcare insurance claims data, and therefore,
COPD severity-specific clinical data were not available.
The association between treatment complexity and
worse outcomes observed in this study may be explained by
the poor treatment adherence and persistence that were
observed in patients using multiple inhalers.13 (Results not
presented in the current manuscript.) Poor treatment
adherence and persistence, combined with a potential forTable 5 Comparisons of mean number and incremental number
multiple-inhaler cohorts.
Number of exacerbations (mean 
Single-inhaler
cohort [A]
Multiple-inhale
cohort [B]
Any exacerbation 1.03  2.63 1.55  3.59
Exacerbation diagnosis 0.36  1.60 0.58  2.26
Outpatient 0.17  0.85 0.27  1.20
Inpatient 0.18  1.15 0.31  1.67
Emergency room 0.01  0.13 0.02  0.14
Exacerbation urgent care 0.43  1.79 0.67  2.52
Inpatient 0.04  0.25 0.05  0.25
Emergency room 0.40  1.75 0.62  2.49
Exacerbation prescription 0.53  1.32 0.78  1.61
* Significant at the 5% level.
** Significant at the 1% level.
a Coefficient > 1 indicates that multiple-inhaler users had a more e
b Multivariate regression models were adjusted for confounding fac
baseline, CCI, prior COPD drug use, and COPD associated comorbiditihigher disease severity, may contribute to poor disease
control (i.e., more exacerbation events) which is likely to
induce significantlymore healthcare resource utilization and
be more expensive for healthcare providers. Indeed,
a concurrent study by the authors based on the same pop-
ulation13 showed that after adjusting for an exhaustive list of
baseline characteristics, multiple-inhaler users had a 40%
higher discontinuation rate compared with single-inhaler
users. Multiple-inhaler users were also less adherent than
single-inhaler users with an average PDC of 0.51 versus 0.55,
respectively. These results, when combinedwith the findings
of the present study as well as the evidence that poor
adherence is associated with a higher risk of exacerbations11
and exacerbations are associated with a substantial clinical
and economic burden,9 suggest that therapeutic strategies
that improve patient adherence, such as simplifyingof exacerbations during the study period between single- and
SD) Unadjusted
incremental
number of
exacerbationsa
[BeA]
P-Value Adjusted
incremental
number of
exacerbation
eventsb
P-Value
r
0.521 <.0001** 0.524 <.0001**
0.223 <.0001** 0.220 <.0001**
0.099 <.0001** 0.097 <.0001**
0.124 <.0001** 0.124 <.0001**
0.003 0.073 0.003 0.092
0.234 <.0001** 0.237 <.0001**
0.009 0.002** 0.009 0.003**
0.224 <.0001** 0.227 <.0001**
0.243 <.0001** 0.244 <.0001**
xacerbation events compared to single-inhaler users.
tors including patient demographics, number of exacerbations at
es.
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tering medication, may be effective in improving the
effectiveness of COPD therapy. Thereby, patients would be
more likely to achieve optimal clinical benefits which would
reduce healthcare use and expenditures. Thus, payers
should consider formulary strategies that encourage the use
of simplified treatment regimens such as combination
inhalers, easy to use devices, and non-inhaled COPD medi-
cations. Future work should be done to further elucidate theTable 6 Comparison of healthcare resource utilization during th
Number of events (per patient-year)
Single-inhaler
users
Multiple-inhaler
users
All-cause
Inpatient admissions 0.32 0.36
Inpatient days 2.09 2.43
Emergency room visits 1.15 1.00
Urgent care visitsd 3.24 3.43
Outpatient visits 43.84 45.57
Other medical servicesc 9.63 10.66
COPD-related
Inpatient admissions 0.03 0.05
Inpatient days 0.17 0.30
Emergency room visits 0.02 0.02
Urgent care visitsd 0.19 0.32
Outpatient visits 2.02 3.20
Other medical servicesc 2.62 3.25
*Significant at the 5% level.
**Significant at the 1% level.
a IRR > 1 indicates that multiple-inhaler users had more studied ou
b Multivariate regression models were adjusted for confounding fac
baseline medical resource use, and COPD associated comorbidities.
c Other medical services include items such as single delivery po
nebulizers.
d Urgent care visits were defined as IP þ ER.link between treatment complexity, treatment adherence,
and outcomes in COPD.Limitations
Besides the potential selection bias by treatment severity,
this study is also subject to the common limitations of this
type of retrospective, observational study based one study period between single- and multiple-inhaler cohorts.
Unadjusted IRRa
(95% CI)
P-Value Adjustedb IRR
(95% CI)
P-Value
1.12 (1.07e1.18) <.0001** 1.15 (1.09e1.21) <.0001**
1.16 (1.08e1.25) 0.0001** 1.20 (1.11e1.30) <.0001**
0.87 (0.77e0.97) 0.0152* 0.93 (0.84e1.04) 0.2271
1.06 (0.99e1.13) 0.0971 1.10 (1.04e1.18) 0.0026**
1.04 (1.01e1.07) 0.0042** 1.06 (1.03e1.09) <.0001**
1.11 (1.06e1.16) <.0001** 1.12 (1.07e1.18) <.0001**
1.64 (1.42e1.88) <.0001** 1.64 (1.43e1.89) <.0001**
1.81 (1.53e2.15) <.0001** 1.82 (1.54e2.16) <.0001**
1.13 (0.74e1.74) 0.5756 1.27 (0.84e1.91) 0.2617
1.74 (1.48e2.04) <.0001** 1.76 (1.50e2.07) <.0001**
1.59 (1.51e1.67) <.0001** 1.59 (1.51e1.68) <.0001**
1.24 (1.16e1.33) <.0001** 1.24 (1.16e1.32) <.0001**
tcomes compared to single-inhaler users.
tors including patient demographics, CCI, prior COPD drug use,
rt oxygen concentrators, portable gaseous oxygen systems and
Table 7 Comparisons of healthcare costs between single- and multiple-inhaler cohorts (US$2008).
Cost component Annual costs (US $2008; mean  SD) Unadjusted
cost
differencea
P-Value Adjustedb
cost
difference
P-Value
Single-inhaler
users
Multiple-inhaler
users
All-cause
Inpatient costs 4873  21,281 5382  20,502 510 <.0001** 519 0.0080**
Emergency room costs 171  1050 165  1088 6 0.9515 2 0.7186
Urgent care costs 5044  21,401 5548  20,613 504 <.0001** 600 <.0001**
Outpatient costs 5206  10,867 5516  10,305 309 <.0001** 410 0.0080**
Other medical service costsc 1387  5053 1576  5939 189 <.0001** 251 <.0001**
Total medical costs 11,636 ± 27,818 12,638 ± 26,591 1002 <.0001** 1586 <.0001**
Pharmacy costs 5372  4657 7013  5163 1642 <.0001** 1776 <.0001**
Total health care costs 17,007 ± 28,806 19,650 ± 27,838 2642 <.0001** 3319 <.0001**
COPD-related
Inpatient costs 245  2302 450  3331 205 <.0001** 199 <.0001**
Emergency room costs 12  297 12  135 0 0.0018** 3 0.3313
Urgent care costs 258  2341 463  3341 205 <.0001** 204 <.0001**
Outpatient costs 185  473 331  813 146 <.0001** 142 <.0001**
Other medical service costsc 337  1187 458  1460 121 <.0001** 138 <.0001**
Total medical costs 779 ± 2878 1251 ± 4034 473 <.0001** 520 <.0001**
Pharmacy costs 782  756 1749  1033 967 <.0001** 976 <.0001**
Total health care costs 1560 ± 3012 3000 ± 4229 1440 <.0001** 1516 <.0001**
*Significant at the 5% level.
**Significant at the 1% level.
The rows in bold correspond to the sum of the above. Therefore, total medical costs is the sum of (inpatient, ER, urgent care, outpatient
and other medical service costs). Similarly, total healthcare costs is in bold because it is the sum of total medical costs and pharmacy
costs.
a Cost difference >0 indicates that multiple-inhaler users had higher healthcare costs compared to single-inhaler users.
b Multivariate regression models were adjusted for confounding factors including patient demographics, CCI, prior COPD drug use, and
COPD associated comorbidities.
c Other medical service costs include costs for items such as single delivery port oxygen concentrators, portable gaseous oxygen
systems and nebulizers.
1870 A.P. Yu et al.healthcare claims data. The accuracy of data was depen-
dent on the accuracy and completeness of original data for
diagnosis and treatment procedures. However, errors and
omissions in the database were expected to affect both
cohorts to a similar extent and unlikely to alter the
conclusions.
Another potential limitation of this study is that a rela-
tively large proportion of patients were not matched and
therefore not included in the study. However, patients
were matched based on a very exhaustive list of baseline
characteristics, resulting in the selection of only patients
with very similar characteristics. This rigorous matching
technique was applied in order to reduce the potential
selection bias by treatment severity and to attempt to
isolate the impact of using a single-inhaler versus multiple
inhalers. Therefore, the association between the use of
multiple inhalers and the increased risk of exacerbation
events, higher resource utilization, and higher costs is likely
to be due to treatment complexity. However, it could also
be due to a potential difference in COPD severity between
single- and multiple-inhaler users, which was not possible
to control for given the absence of direct clinical measures
of severity.
Finally, although this analysis defined exacerbation
events in four different ways, it is possible that the actual
number of exacerbation events was underestimated. Sinceit is not possible to clearly identify exacerbation events on
claims data (our definitions are only based on healthcare
resource use utilization), it is not possible to paint
a complete picture of every individual’s COPD exacerbation
related history.
Conclusions
In this study, patients with COPD using multiple long-acting
inhalers had higher risks of experiencing an exacerbation
event and experienced a greater number of exacerbations
compared to patients using a single long-acting inhaler.
Multiple-inhaler users also required significantly higher
healthcare resources and incurred higher healthcare costs,
beyond those associated solely with the use of an additional
medication, when compared to single-inhaler users.
However, the findings of this study should be interpreted
with caution given the lack of control for clinical measures
of COPD severity.
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